Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECAP Pilot: Psilocybin and Midazolam in Healthy Volunteers
NCT04842045Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- May 2021
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in major depressive disorder (MDD), sponsored by University of Wisconsin–Madison. Primary endpoint: Altered States of Consciousness Questionnaire Score at Day 15. Started May 2021; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04842045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842045.